2024
Carbon monoxide-loaded red blood cells ameliorate metabolic dysfunction-associated steatohepatitis progression via enhancing AMP-activated protein kinase activity and inhibiting Kupffer cell activation
Yanagisawa H, Maeda H, Noguchi I, Tanaka M, Wada N, Nagasaki T, Kobayashi K, Kanazawa G, Taguchi K, Chuang V, Sakai H, Nakashima H, Kinoshita M, Kitagishi H, Iwakiri Y, Sasaki Y, Tanaka Y, Otagiri M, Watanabe H, Maruyama T. Carbon monoxide-loaded red blood cells ameliorate metabolic dysfunction-associated steatohepatitis progression via enhancing AMP-activated protein kinase activity and inhibiting Kupffer cell activation. Redox Biology 2024, 76: 103314. PMID: 39163766, PMCID: PMC11381851, DOI: 10.1016/j.redox.2024.103314.Peer-Reviewed Original ResearchAMP-activated protein kinaseKupffer cell activationHeme oxygenase-1Red blood cellsInhibit Kupffer cell activationLiver heme oxygenase-1Suppress Kupffer cell activationCell activationLiver regenerationModel miceBlood cellsFat accumulationActivating AMP-activated protein kinaseAMP-activated protein kinase activationImpaired liver regenerationMethionine-choline deficient dietNonalcoholic fatty liver diseaseRestore liver regenerationFatty liver diseaseReceptor inductionHealthy miceProtein kinase activityPromoting fatty acid oxidationMouse modelLiver disease
2021
Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH
Maeda H, Ishima Y, Saruwatari J, Mizuta Y, Minayoshi Y, Ichimizu S, Yanagisawa H, Nagasaki T, Yasuda K, Oshiro S, Taura M, McConnell MJ, Oniki K, Sonoda K, Wakayama T, Kinoshita M, Shuto T, Kai H, Tanaka M, Sasaki Y, Iwakiri Y, Otagiri M, Watanabe H, Maruyama T. Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH. Journal Of Controlled Release 2021, 341: 457-474. PMID: 34856227, DOI: 10.1016/j.jconrel.2021.11.039.Peer-Reviewed Original ResearchConceptsMannose receptor C type 1Treatment of NASHNonalcoholic steatohepatitisKupffer cellsBlood flowNO donorReactive oxygen speciesHepatic blood flowDevelopment of steatohepatitisNASH model miceC type 1Nitric oxide donorOxidative stress-associated pathologiesStress-associated pathologiesCombination therapyHepatoprotective effectModel miceLiver lobeOxide donorType 2Therapeutic potentialType 1Nitric oxidePathological phenotypesSpecific uptake
2018
Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions
Minayoshi Y, Maeda H, Yanagisawa H, Hamasaki K, Mizuta Y, Nishida K, Kinoshita R, Enoki Y, Imafuku T, Chuang VTG, Koga T, Fujiwara Y, Takeya M, Sonoda K, Wakayama T, Taguchi K, Ishima Y, Ishida T, Iwakiri Y, Tanaka M, Sasaki Y, Watanabe H, Otagiri M, Maruyama T. Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions. Drug Delivery 2018, 25: 1055-1065. PMID: 29688069, PMCID: PMC6058604, DOI: 10.1080/10717544.2018.1464083.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnti-Inflammatory AgentsB7-H1 AntigenCell LineHepatitisHumansImmunologic FactorsInterferon alpha-2Interferon Type IInterferon-alphaInterleukin 1 Receptor Antagonist ProteinInterleukin-10Kupffer CellsLiverMaleMannoseMiceMice, Inbred C57BLMice, Inbred ICRRAW 264.7 CellsRecombinant ProteinsSerum AlbuminConceptsKupffer cellsImmunomodulatory actionsTypes of hepatitisHepato-protective effectsTreatment of hepatitisAlbumin fusion technologyIL-10Liver injuryPD-L1IL-1raImmunomodulatory effectsModel miceTherapeutic effectivenessSurvival rateIFNα2bRAW264.7 cellsHepatitisInterferon receptorMRNA levelsSignificant inductionConcanavalin AMenMiceConcept studyCells